INTEGRATED LABORATORY ABNORMALITY PROFILES OF UPADACITINIB WITH UP TO 4.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED IN THE SELECT PHASE 3 PROGRAM

被引：0

作者：

Charles-Schoeman, C. ^{[1
]}

Giles, J. T. ^{[2
]}

Lane, N. ^{[3
]}

Choy, E. ^{[4
]}

Furst, D. ^{[5
]}

Vencovsky, J. ^{[6
]}

Wilson, A. G. ^{[7
]}

Burmester, G. R. ^{[8
]}

Shaw, T. ^{[9
]}

Song, Y. ^{[9
]}

Camp, H. ^{[9
]}

Khan, N. ^{[9
]}

Yee, J. ^{[9
]}

Anyanwu, S. ^{[9
]}

Mcinnes, I. ^{[10
]}

机构：

[1] Univ Calif Los Angeles, Rheumatol, Los Angeles, CA USA

[2] Columbia Univ, Rheumatol, New York, NY USA

[3] Univ Calif Davis, Rheumatol, Sacramento, CA USA

[4] Cardiff Univ, CREATE Ctr, Rheumatol, Cardiff, Wales

[5] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[6] Inst Rheumatol, Rheumatol, Prague, Czech Republic

[7] Univ Coll Dublin, Conway Inst, Ctr Arthrit Res, Dublin, Ireland

[8] Charite, Rheumatol, Berlin, Germany

[9] AbbVie Inc, Immunol, N Chicago, IL USA

[10] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷

关键词：

D O I：

10.1136/annrheumdis-2021-eular.1815

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0128

引用

页码：72 / 73

页数：2

共 50 条

[1] Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Years of Exposure in Patients with Rheumatoid Arthritis Treated in a Phase 3 Clinical Trial
Charles-Schoeman, Christina
Giles, Jon
Lane, Nancy
Choy, Ernest
Furst, Dan
Vencovsky, Jiri
Wilson, Anthony
Burmester, Gerd
Shaw, Tim
Song, Yanna
Camp, Heidi
Khan, Nasser
Yee, Jillian
Anyanwu, Samuel
McInnes, Iain
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3513 - 3516
[2] INTEGRATED SAFETY PROFILE OF UPADACITINIB WITH UP TO 4.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Cohen, S. B.
Van Vollenhoven, R.
Curtis, J. R.
Calabrese, L.
Zerbini, C.
Tanaka, Y.
Bessette, L.
Richez, C.
Lagunes-Galindo, I.
Liu, J.
Camp, H.
Song, Y.
Anyanwu, S.
Burmester, G. R.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 328 - 329
[3] INTEGRATED SAFETY PROFILE OF UPADACITINIB WITH UP TO 4.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Cohen, Stanley B.
van Vollenhoven, Ronald
Curtis, Jeffrey R.
Calabrese, Leonard
Zerbini, Cristiano A. F.
Tanaka, Yoshiya
Bessette, Louis
Richez, Christophe
Lagunes-Galindo, Ivan
Liu, Jianzhong
Camp, Heidi S.
Song, Yanna
Anyanwu, Samuel I.
Burmester, Gerd R.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S105 - S105
[4] Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis
Cohen, Stanley
Van Vollenhoven, Ronald F.
Curtis, Jeffrey
Calabrese, Leonard
Zerbini, Cristiano A. F.
Tanaka, Yoshiya
Bessette, Louis
Schlacher, Casey
Shaw, Tim
Liu, John
Enejosa, Jeffrey
Song, Yanna
Burmester, Gerd
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[5] SAFETY PROFILE OF UPADACITINIB UP TO 3 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Cohen, S. B.
Van Vollenhoven, R.
Curtis, J. R.
Calabrese, L.
Zerbini, C.
Tanaka, Y.
Bessette, L.
Schlacher, C.
Shaw, T.
Liu, J.
Enejosa, J. J.
Song, Y.
Burmester, G. R.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 315 - 316
[6] SAFETY PROFILE OF UPADACITINIB IN RHEUMATOID ARTHRITIS: INTEGRATED ANALYSIS FROM THE SELECT PHASE 3 CLINICAL PROGRAM
Cohen, Stanley B.
van Vollenhoven, Ronald
Winthrop, Kevin
Zerbini, Cristiano
Tanaka, Yoshiya
Bessette, Louis
Li Yihan
Khan, Nasser
Hendrickson, Barbara
Burmester, Gerd Ruediger
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 357 - 357
[7] Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program
Kakehasi, Adriana Maria
Radominski, Sebastiao Cezar
Baravalle, Marcos Daniel
Palazuelos, Fedra Consuelo Irazoque
Garcia-Garcia, Conrado
Arruda, Maysa Silva
Curi, Marco
Liu, John
Qiao, Meihua
Velez-Sanchez, Patricia
Vargas, Juan Ignacio
CLINICAL RHEUMATOLOGY, 2023, 42 (05) : 1249 - 1258
[8] Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program
Adriana Maria Kakehasi
Sebastião Cezar Radominski
Marcos Daniel Baravalle
Fedra Consuelo Irazoque Palazuelos
Conrado Garcia-Garcia
Maysa Silva Arruda
Marco Curi
John Liu
Meihua Qiao
Patricia Velez-Sanchez
Juan Ignacio Vargas
Clinical Rheumatology, 2023, 42 : 1249 - 1258
[9] SAFETY PROFILE OF UPADACITINIB IN RHEUMATOID ARTHRITIS: INTEGRATED ANALYSIS FROM THE SELECT PHASE 3 CLINICAL PROGRAM
Cohen, Stanley B.
van Vollenhoven, Ronald
Winthrop, Kevin
Zerbini, Cristiano A. F.
Tanaka, Yoshiya
Bessette, Louis
Zhang, Ying
Khaff, Nasser
Hendrickson, Barbara
Enejosa, Jeffrey V.
Burmesters, Gerd
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 10 - 10
[10] Safety Profile of Upadacitinib in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program
Cohen, Stanley
van Vollenhoven, Ronald
Winthrop, Kevin
Zerbini, Cristiano A.
Tanaka, Yoshiya
Bessette, Louis
Zhang, Ying
Khan, Nasser
Hendrickson, Barbara
Enejosa, Jose Jeffrey
Burmester, Gerd
ARTHRITIS & RHEUMATOLOGY, 2019, 71

← 1 2 3 4 5 →